Detailed Information on Publication Record
2024
Human Endogenous Retroviruses in Breast Cancer: Altered Expression Pattern Implicates Divergent Roles in Carcinogenesis
ZAVESKY, Ludek, Eva JANDÁKOVÁ, Vít WEINBERGER, Luboš MINÁŘ, Milada KOHOUTOVA et. al.Basic information
Original name
Human Endogenous Retroviruses in Breast Cancer: Altered Expression Pattern Implicates Divergent Roles in Carcinogenesis
Authors
ZAVESKY, Ludek, Eva JANDÁKOVÁ, Vít WEINBERGER, Luboš MINÁŘ, Milada KOHOUTOVA and Ondrej SLANAR
Edition
Oncology, Basel, Karger, 2024, 0030-2414
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
Switzerland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 3.500 in 2022
Organization unit
Faculty of Medicine
UT WoS
001243070800001
Keywords in English
Breast cancer; Human endogenous retroviruses; ERVW-1; ERVFRD-1; ERVV-1; ERV3-1; ERVH48-1; ERVMER34-1; ERVK13-1; ERVK3-1; HCP5
Tags
International impact, Reviewed
Změněno: 2/7/2024 09:53, Mgr. Tereza Miškechová
Abstract
V originále
Introduction: Breast cancer is the most common cancer and the leading cause of cancer death in women. Recent research indicates that human endogenous retroviruses (HERVs) may be linked to carcinogenesis, but the data remain controversial. Methods: HERVs' expression was evaluated to show the differences between breast cancer and control samples, and their associations with clinicopathological parameters. Gene expression of 12 HERVs, i.e., ERVE-4, ERVW-1, ERVFRD-1, ERVV-1, ERV3-1, ERVH48-1, ERVMER34-1, ERVK-7, ERVK13-1, ERVK11-1, ERVK3-1, and HCP5, was analyzed by qPCR and/or TCGA datasets for breast cancer. Results: ERV3-1, ERVFRD-1, ERVH48-1, and ERVW-1 provided data to support their tumor suppressor roles in breast cancer. ERV3-1 evinced the best performing diagnostic data based on qPCR, i.e., AUC: 0.819 (p < 0.0001), sensitivity of 72.41%, and specificity of 89.66%. Lower levels of ERV3-1 were noted in advanced stage and higher grades, and significant negative association was found in relation to Ki-67 levels. Oncogenic roles may be inferred for ERVK13-1, ERVV-1, and ERVMER34-1. Data for ERVK-7, ERVE-4, ERVK11-1, and HCP5 remain inconclusive. Conclusion: Differential HERV expression may be applicable to evaluate novel biomarkers for breast cancer. However, more research is needed to reveal their real clinical impact, the biological roles, and regulatory mechanisms in breast carcinogenesis. (c) 2024 The Author(s).Published by S. Karger AG, Basel